Oragenics, Inc.
OGEN · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.63 | 2.20 | 1.35 |
| FCF Yield | -11.72% | -1.92% | -4.04% | -0.89% |
| EV / EBITDA | -6.90 | -18.05 | -25.95 | -94.82 |
| Quality | ||||
| ROIC | -9,052.41% | -305.64% | -104.83% | -57.86% |
| Gross Margin | 0.00% | -72.75% | 66.04% | 52.59% |
| Cash Conversion Ratio | 0.81 | 0.35 | 1.07 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -17.92% | 52.52% | -13.63% | 20.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.15 | 0.76 | 1.69 |
| Interest Coverage | -354.00 | -348.76 | -954.84 | -1,000.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -101.54 | -29.33 | -2,015.85 | -7,538.37 |